Ebola vaccine work reported progress toward broader protection across multiple filovirus species. Researchers described a nanoparticle pan-Ebolavirus vaccine that protected rodents against lethal Zaire and Sudan virus infections, aiming to address the persistent challenge of species diversity in filovirus medicine. In parallel, engineered AAV vector manufacturing work reported a redesign of helper plasmids to increase AAV production by tuning expression of adenoviral regulatory factors. While not a clinical efficacy result, the manufacturing improvement targets a major bottleneck for gene therapy delivery. Combined, the items reflect a two-track push in viral therapeutics: broader neutralization coverage for vaccines and more scalable manufacturing for vector-based treatments.